These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 19176991

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 25. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K.
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [Abstract] [Full Text] [Related]

  • 26. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
    Bajou K.
    Bull Mem Acad R Med Belg; 2002 Jul; 157(5-6):313-8. PubMed ID: 12557575
    [Abstract] [Full Text] [Related]

  • 27. The fibrinolytic system in neoplasia.
    Bell WR.
    Semin Thromb Hemost; 1996 Jul; 22(6):459-78. PubMed ID: 9122711
    [Abstract] [Full Text] [Related]

  • 28. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
    Serratì S, Margheri F, Bruschi S, D'Alessio S, Pucci M, Fibbi G, Tonelli P, Del Rosso M.
    Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
    [Abstract] [Full Text] [Related]

  • 29. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
    Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G.
    Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
    [Abstract] [Full Text] [Related]

  • 30. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 31. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease.
    Agirbasli M.
    Int J Clin Pract; 2005 Jan; 59(1):102-6. PubMed ID: 15707473
    [Abstract] [Full Text] [Related]

  • 32. [Plasminogen activator system and its clinical significance in patients with a malignant disease].
    Halámková J, Kiss I, Tomásek J, Pavlovský Z, Cech Z, Tutek S, Hanáková L, Moulis M, Penka M.
    Klin Onkol; 2011 Jan; 24(6):418-23. PubMed ID: 22257230
    [Abstract] [Full Text] [Related]

  • 33. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 34. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, Kim SU, Aboody KS.
    Stem Cells; 2008 Jun 15; 26(6):1406-13. PubMed ID: 18403751
    [Abstract] [Full Text] [Related]

  • 35. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 15; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 36. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 15; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 37. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 15; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 38. Evolving role of uPA/uPAR system in human cancers.
    Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH.
    Cancer Treat Rev; 2008 Apr 15; 34(2):122-36. PubMed ID: 18162327
    [Abstract] [Full Text] [Related]

  • 39. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A, Cinelli M, Guiducci S, Pignone A, Fibbi G, Margheri F, Gabrielli A, Giacomelli R, Coppini A, Del Rosso M, Matucci Cerinic M.
    Rheumatology (Oxford); 2005 Oct 15; 44(10):1255-62. PubMed ID: 15998634
    [Abstract] [Full Text] [Related]

  • 40. Plasminogen activators and cancer.
    Duffy MJ.
    Blood Coagul Fibrinolysis; 1990 Dec 15; 1(6):681-7. PubMed ID: 2133247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.